SALIRI-based (raltitrexed plus irinotecan) therapy as a second-line treatment for patients with metastatic colorectal cancer (SALLY): A prospective, multicenter, non-interventional, registry study.
Qin S, Li J, Zhou A, Zhang Y, Yuan X, Zhu L, Qin B, Zeng S, Shen L, Yuan Y, Wang W, Liang J, Zhang X, Ye F, Chen P, Wang H, Yu Z, Yue L, Fang Y, Xiong J, Yang J, Wan Y, Yin X, Wang W, Xu N, Wang X, Xiao Z, Su H, Wang Y, Gu K, Tu S, Wang Z, Liu B, Hu X, Liu W, Li X.
Qin S, et al. Among authors: zhu l.
Cancer Commun (Lond). 2024 Aug;44(8):910-914. doi: 10.1002/cac2.12586. Epub 2024 Jul 8.
Cancer Commun (Lond). 2024.
PMID: 38976318
Free PMC article.
No abstract available.